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Abstract
Background: Obesity is a chronic low inflammatory state. In the obesity condition the white adipose
tissue (WAT) is massively infiltrated with monocytes/macrophages, and the nature of the signals recruiting
these inflammatory cells has yet to be fully elucidated. Haptoglobin (Hp) is an inflammatory marker and its
expression is induced in the WAT of obese subjects. In an effort to elucidate the biological significance of
Hp presence in the WAT and of its upregulation in obesity we formulated the hypothesis that Hp may
serve as a macrophage chemoattractant.
Results: We demonstrated by chemotaxis assay that Hp is able to attract chemokine (C-C motif)
receptor 2 (CCR2)-transfected pre-B lymphocytes and monocytes in a dose-dependent manner.
Moreover, Hp-mediated migration of monocytes is impaired by CCR2-specific inhibition or previous cell
exposure to monocyte chemoattractant protein 1 (MCP1) (also known as CCR2 ligand or chemokine (C-
C motif) ligand 2 (CCL2)). Downstream effects of Hp/CCR2 interaction were also investigated: flow
cytometry proved that monocytes treated with Hp show reduced CCR2 expression on their surface; Hp
interaction induces calcium release that is reduced upon pretreatment with CCR2 antagonist; extracellular
signal-regulated kinase (ERK)1/2, a signal transducer activated by CCR2, is phosphorylated following Hp
treatment and this phosphorylation is reduced when cells are pretreated with a specific CCR2 inhibitor.
Consistently, blocking the ERK1/2 pathway with U0126, the selective inhibitor of the ERK upstream
mitogen-activated protein (MAP)-ERK kinase (MEK), results in a dramatic reduction (by almost 100%) of
the capability of Hp to induce monocyte migration.
Conclusions: Our data show that Hp is a novel monocyte chemoattractant and that its chemotactic
potential is mediated, at least in part. by its interaction with CCR2.
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Background
Haptoglobin (Hp) is an acute phase protein synthesized
by the liver, and its serum concentrations are elevated dur-
ing inflammation. Several functions have been attributed
to this protein including its ability to bind free hemo-
globin, thus preventing oxidative damage, and its capacity
to induce angiogenesis [1]. Hp is also expressed by murine
and human white adipose tissue (WAT) and, as reported
previously, its expression is induced in obesity [2,3].
According to Fain et al. [4], Hp is released both by human
isolated adipocytes and the adipose tissue matrix, but not
by cells of the stromal vascular fraction (SVF). This result
is in agreement with the observation of do Nascimento et
al. [5], who showed that in murine adipose tissue Hp is
one of those few inflammatory molecules specifically pro-
duced by adipocytes and not present in the SVF. Taken
together, these data point to Hp as a novel adipokine as
well as a further molecule marking the intersection
between obesity and inflammation.
Indeed, the most recent theories [6] describe obesity as a
low chronic inflammatory state, and this has been impli-
cated in the development of common medically impor-
tant complications, including atherosclerosis, hepatic
steatosis and insulin resistance [7-9]. Markers of the obes-
ity-induced inflammatory state are the augmented pro-
duction by adipose tissue, liver and muscle of
proinflammatory proteins such as Hp, procoagulant fac-
tors, cytokines and chemokines. It is also known that
obesity is associated with increased infiltration of macro-
phages in the WAT, but not in liver and muscle [10]. This
accumulation of monocytes/macrophages certainly con-
tributes to the inflammatory-like gene expression pattern
displayed by the adipose tissue of the obese, and strong
evidence suggests a causal role for macrophages in the
onset of insulin resistance in mice [11]. The mechanisms
underlying macrophage recruitment are still a matter of
investigation, and likely involve increased secretion of
chemotactic molecules by the adipocytes. A critical role as
a modulator of the influx of monocytes in WAT has been
established for the couple ligand/receptor monocyte che-
moattractant protein 1 (MCP1; also known as chemokine
(C-C motif) receptor 2 (CCR2) ligand or chemokine (C-C
motif) ligand 2 (CCL2)) [12,13].
In an effort to further elucidate the biological significance
of Hp's presence in the WAT and of its upregulation in
obesity we formulated the hypothesis that Hp may serve
as a macrophage chemoattractant. We addressed the
present issue in vitro by assessing the capacity of Hp to
attract monocytes (both primary and established cell
lines). Our results provide convincing evidence that the
starting hypothesis is correct. Further, they suggest that the
capacity of Hp to induce macrophage migration is at least
partly mediated by its interaction with a chemokine recep-
tor and by the activation of a mitogen-activated protein
(MAP) kinase (MAPK) pathway.
Results
Haptoglobin chemotaxis studies
To our knowledge Hp chemotactic activity has never been
previously reported. To assess the capacity of this glyco-
protein to attract monocytes/macrophages we performed
chemotaxis assays with an established cell line of human
monocytes (U937 cells) and with primary monocytes iso-
lated from healthy donors. For both cell types Hp induced
a dose-dependent and positive effect on monocyte migra-
tion, as shown in the representative curves of Figure 1a, b.
MCP1 was used as a positive control. We obtained similar
results in five additional experiments, which overall indi-
cated a significant effect of Hp on monocyte migration
starting from concentrations of 0.05 and 0.1 mg/ml
(approximately 0.435 and 0.87 μM, respectively). This is
indicated as an approximate concentration, since in most
cases we employed a purchased mixture of the three major
human Hp phenotypes, namely 1-1, 2-2 and 2-1 and a
precise calculation cannot be performed. For this reason
doses employed will be indicated herein with weight/vol-
ume measurement units. Hp circulates in human plasma
at concentrations ranging from 0.3 to 3 mg/ml (approxi-
mately 2.61 to 26.1 μM) [3,14-16] and doses employed
throughout the study are within this range or lower.
MCP1 was used at concentrations between 10 and 100 ng/
ml (1.15 to 11.5 nM), known to induce maximal chemo-
tactic response as reported in the literature [17] and
directly assessed in our laboratory (data not shown). The
use of Hp in the ng range with human cells would be of
scarce physiological significance, given the much higher
doses of the protein to which human tissues are normally
exposed. To control for possible aspecific effects due to
the high amount of the protein employed in case of Hp,
experiments were always performed employing similarly
high doses of a neutral agent (bovine serum albumin
(BSA)) as negative control. BSA did not show chemotactic
effects at doses as high as 1 mg/ml (15.1 μM). Results
totally overlapping with those shown for U937 undiffer-
entiated monocytes were obtained when U937 cells were
induced to differentiate to macrophages (data not
shown).
Since in migration assays cells can only move in one direc-
tion (that is, towards the filter membrane), the assay must
be set up to discriminate between directional and random
migration. By following the method established by Heit et
al. [18] we tested migration across membranes where a
chemotactic gradient existed across the membrane (that
is, chemoattractant only in the lower well), as well as
across membranes where a uniform concentration of che-
moattractant was present (that is, chemoattractant in both
wells). If the ratio between the number of cells migratingBMC Biology 2009, 7:87 http://www.biomedcentral.com/1741-7007/7/87
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in the gradient versus the number moving in the uniform
concentration (termed the chemotactic ratio) is <1 the
cells are moving randomly. Chemotactic ratios of >1 sug-
gest that the cells are undergoing chemotaxis. When U937
cells were used we obtained a chemotactic ratio of 1.81 for
Hp (tested at 0.5 mg/ml) and of 1.41 for MCP1 (100 ng/
ml). This enabled us to establish that what we observed
was directional chemotaxis and not chemokinesis.
In the experiments presented in this study we used a pur-
chased mixture of the three Hp phenotypes, namely 1-1,
2-2, and 2-1 (purity 95%). To further confirm our results
we performed chemotaxis experiments on U937 mono-
cytes employing the two Hp phenotypes (1-1 and 2-2) at
higher purity (98 to 100%) separately or together as a
home-made mixture. Data are shown in the bar graphs of
Figure 1c, d and indicate that: (1) increasing Hp purity
(98% to 100% versus 95%) results in a moderate increase
in Hp chemotactic power as demonstrated by the gener-
ally increased number of migrated cells toward the 98%
pure preparation (Figure 1c), this ruling out the possibil-
ity that copurified contaminants (higher in the less puri-
Effect of haptoglobin (Hp) on U937 monocytes (a, c and d) and human primary monocytes migration (b) Figure 1
Effect of haptoglobin (Hp) on U937 monocytes (a, c and d) and human primary monocytes migration (b). (a) 
Chemotaxis was performed on U937 cells for 3 h at the indicated doses of Hp and monocyte chemoattractant protein 1 
(MCP1). In the case of the negative control bovine serum albumin (BSA) (1 mg/ml) was used. (b) Chemotaxis was performed 
on primary monocytes for 90 min. One-way analysis of variance (ANOVA), P < 0.0001. Bonferroni post-test versus BSA *P < 
0.05, ***P < 0.001. (c, d) Chemotaxis was performed on U937 cells for 3 h at the indicated doses. Migrated cells are expressed 
as percentage of the average number of migrated cells in the negative control wells (BSA, 1 mg/ml). (c) Bar graph showing the 
comparison between the chemotactic potential of Hp 95% pure (premade mixture of phenotypes 1-1, 2-1 and 2-2, light gray 
bars) and that of Hp 98% to 100% pure (homemade mixtures of phenotypes 1-1 and 2-2, dark gray bars). One-way ANOVA, P 
< 0.0001. Bonferroni post-test versus BSA *P < 0.05, **P < 0.01, ***P < 0.001. Bonferroni post-test Hp 95% versus Hp 98% to 
100% $P < 0.05. (d) Bar graph showing the comparison between chemotactic potential of Hp 1-1 (light gray bars) versus Hp 2-
2 (dark gray bars). One-way ANOVA, P < 0.0001. Bonferroni post-test versus BSA **P < 0.01, ***P < 0.001. Bonferroni post-
test Hp 1-1 versus Hp 2-2 $P < 0.05. Data are expressed as means ± standard error of the mean (SEM) of migrated cells for at 
least three independent experiments.
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fied reagent) other than Hp itself may be responsible for
the observed cell migration; (2) the two isoforms slightly
differ in that 2-2 at 0.5 and 0.1 mg/ml concentration
shows a moderately albeit significantly higher chemotac-
tic potential (Figure 1d). Differences between the use of
the 95% pure and 98% to 100% pure reagents were not
considered substantial for the main purpose of this study
and the experiments described in the following para-
graphs were performed using the 95% recombinant Hp.
Pre-B lymphocytes stably expressing CCR2 are 
functionally responsive to Hp
The results above indicate that Hp is able to induce chem-
otaxis. It is well accepted that monocyte and macrophage
migration is principally mediated by chemokine-like fac-
tors. Indeed, monocytes express abundant levels of active
chemokine receptors among which CCR2 has been
importantly implicated in macrophage chemoattraction
[19] to WAT, where Hp is abundantly expressed and
released during obesity. We therefore wanted to evaluate
the possibility that Hp might interact with this receptor.
To address this issue we first evaluated the chemotactic
potential of Hp on murine pre-B cell line 300.19 stably
expressing human CCR2 receptor (300.19-CCR2), con-
sidered a reliable model to test the specific CCR2 response
[20]. Cells transfected with CCR2 migrated towards MCP1
as expected and also positively responded to Hp. 300.19-
CCR2 cells did not show any significant migration
towards the negative control (BSA 1 mg/ml). Parental
cells were neither responsive to MCP1 nor to Hp (Figure
2a).
As calcium flux is one of the most reliable indicators of
signaling through chemokine receptors [21], we also eval-
uated intracellular calcium release in 300.19-CCR2 cells
upon MCP1 (250 ng/ml) and Hp (0.5 mg/ml) stimula-
tion. Hp induced an increase of intracellular free calcium
in cells preloaded with fura-2 acetoxymethyl ester (fura-2
AM): the amplitude of the signal was approximately 40%
of that assessed for MCP1 (Figure 2b). After 300.19-CCR2
cells treatment with the specific CCR2 antagonist
RS102895 (5 μM) cells showed a significant decreased
responsiveness (less than 60%) to MCP1, while Hp-
induced calcium flux was totally abolished (Figure 2b).
Hp did not induce any significant calcium flux in parental
cells or MCP1.
These data indicate that Hp induces functional responses
in pre-B lymphocytes stably expressing CCR2.
Hp-mediated functional response in monocytes is reduced 
by CCR2 agonist or antagonist
We next wanted to investigate the interaction between Hp
and CCR2 by analyzing the extent to which Hp interferes
with the specific CCR2 ligand MCP1 in monocytes. We
performed chemotaxis assays with U937 human mono-
cytes pretreated for 45 min either with MCP1 (500 ng/
ml), the CCR2-specific ligand, Hp (1 mg/ml) or BSA (1
mg/ml), herein used as a neutral agent. Pretreatment with
MCP1 resulted in a complete 100% reduction of cells
migrated towards MCP1 and an approximate 76% reduc-
tion of cells migrated towards Hp. By contrast, pretreat-
ment with Hp completely abolished migration towards
Hp itself and caused a 45% reduction in the capacity of
U937 cells to migrate towards MCP1 (Figure 3a, bar
graph). When higher doses of Hp were employed (2.5 mg/
ml) for pretreatment, the effect was further magnified
with a 91% reduction in the capacity of U937 cells to
migrate towards MCP1. Experiments performed on pri-
mary monocytes gave similar results in that pretreatment
with MCP1 resulted in a 82% reduction of cells migrated
towards MCP1 and 40% reduction of cells migrated
towards Hp, whereas Hp pretreatment caused a 47.5%
reduction of cells migrated towards MCP1 and 79%
reduction of cells migrated towards itself. MCP1 and Hp
are then reciprocally capable of interfering with each other
in their capacity to attract cells, which is consistent with an
interaction with a common receptor.
When U937 cells were incubated for 45 min with the
CCR2-specific antagonist RS102895 (5 μM), cell respon-
siveness to MCP1 was reduced by 100% (as compared
with pretreatment with BSA; see above) and a significant
reduction of 84.5% was observed in the capacity of cells
to migrate towards Hp (0.5 mg/ml) (Figure 3c). After pre-
treatment with RS102895 (5 μM) human primary mono-
cyte migration towards MCP1 and Hp was also
significantly reduced: cells preserved only 46% and 76%,
respectively, of their responsiveness to MCP1 and Hp (Fig-
ure 3d). Blocking CCR2 therefore has a negative effect on
Hp chemotactic activity.
We next evaluated calcium release in U937 cells following
Hp stimulation: in this case, and differently to what was
observed in 300.19-CCR2 cells, MCP1 and Hp stimula-
tion resulted in similar [Ca2+]i mobilization (Figure 4).
After pretreatment with 500 ng/ml MCP1, cells showed a
decreased responsiveness (almost 70%) to 0.5 mg/ml Hp,
suggesting that MCP1 interferes with Hp-induced calcium
flux. Similar results were obtained after pretreatment with
the CCR2 inhibitor RS102895 (65% reduction in calcium
release).
Taken together, these data suggest that CCR2 mediates (at
least in part) the capability of Hp to attract monocytes and
to induce calcium release.
Hp/CCR2 physical interaction
To gain further insights into the type of interaction occur-
ring between Hp and CCR2, we performed binding stud-
ies using U937 cells. The curve in Figure 5 shows that HpBMC Biology 2009, 7:87 http://www.biomedcentral.com/1741-7007/7/87
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is able to displace [125I]MCP1 binding to U937 cells in a
dose-dependent manner, with a 50% inhibition at a Hp
concentration of 2 mg/ml. This suggests that Hp interacts
with CCR2 albeit with a low binding affinity.
Hp induces CCR2 internalization in monocytes
As with other chemokines with agonistic activity, CCR2
activation is followed by internalization [22] and several
studies reported CCR2 disappearance from cell surface
following exposure to MCP1 [21].
To further prove the potential interaction between CCR2
and Hp, we studied the effect of Hp on CCR2 internaliza-
tion. MCP1 (herein used as a positive control) and Hp
pretreatments induced a dose-dependent disappearance
of CCR2 receptor from the surface of U937 cells (Figure
6a) as assessed by flow cytometric analysis.
A similar, albeit less dramatic effect was observed in pri-
mary monocytes (Figure 6b). Differences in CCR2 surface
expression could partly account for the less pronounced
Effect of haptoglobin (Hp) on cell migration and calcium release in pre-B lymphocytes 300.19 stably expressing chemokine (C- C motif) receptor 2 (CCR2) (300.19-CCR2) Figure 2
Effect of haptoglobin (Hp) on cell migration and calcium release in pre-B lymphocytes 300.19 stably expressing 
chemokine (C-C motif) receptor 2 (CCR2) (300.19-CCR2). (a) Chemotaxis was performed on 300.19 and 300.19-
CCR2 cells for 3 h at the indicated doses of Hp and monocyte chemoattractant protein 1 (MCP1). Bovine serum albumin 
(BSA) (1 mg/ml) was used as negative control. Two-way analysis of variance (ANOVA), P < 0.0001. Bonferroni post-test versus 
BSA ***P < 0.001, versus 300.19 parental cells §§§P < 0.001. (b) Left panel, fura-2 acetoxymethyl ester (fura-2 AM) preloaded 
300.12-CCR2 cells untreated or pretreated with 5 μM RS102895 were stimulated with 250 ng/ml MCP1 or 0.5 mg/ml Hp, right 
panel quantification of [Ca2+]i rise in 300.19-CCR2 cells. The rate of [Ca2+]i rise (percentage fura-2 saturation/s) induced by 
MCP1 was set to 100% and the rate after pretreatment was calculated. At the bottom on the left, stimulation of 300.19 paren-
tal cells did not result in any appreciable calcium flux. The results are representative of three independent experiments.
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Monocyte chemoattractant protein 1 (MCP1) and haptoglobin (Hp) show reciprocal interference on the capacity of cells to  migrate Figure 3
Monocyte chemoattractant protein 1 (MCP1) and haptoglobin (Hp) show reciprocal interference on the 
capacity of cells to migrate. (a) Bar graph showing the effect of pretreatment (45 min at 37°C) with MCP1 (500 ng/ml), Hp 
(1 mg/ml) or bovine serum albumin (BSA) (1 mg/ml) on the capacity of U937 cells to migrate towards MCP1 (100 ng/ml white 
bars) and Hp (0.5 mg/ml, black bars). For each treatment the number of cells that migrated towards a chemotactically neutral 
agent (BSA 1 mg/ml) was considered as a baseline and subtracted from the numbers obtained for migration against MCP1 and 
Hp. Data are expressed as means ± standard error of the mean (SEM) of migrated cells for at least four experiments. Two-way 
analysis of variance (ANOVA) on the effect of pretreatment, P < 0.001. Bonferroni post-test versus pretreatment with BSA **P 
< 0.01 for migration towards MCP1, ^P < 0.01 for migration towards Hp. (b) As (a), using human primary monocytes. Two-
way ANOVA on the effect of pretreatment, P < 0.001. Bonferroni post-test versus pretreatment with BSA ***P 0.001 **P < 
0.01 for migration towards MCP1, ^P < 0.05 for migration towards Hp. (c) Bar graph showing the effect of pretreatment with 
the chemokine (C-C motif) receptor 2 (CCR2) synthetic antagonist RS102895 (5 μM) or BSA (1 mg/ml) on the capacity of 
U937 cells to migrate towards MCP1 (100 ng/ml white bars) and Hp (0.5 mg/ml, black bars). For each treatment the number of 
cells migrated towards a chemotactically neutral agent (BSA 1 mg/ml) was considered as a baseline and subtracted from the 
numbers obtained for migration against MCP1 and Hp. Data are expressed as means ± SEM of migrated cells for at least four 
experiments. Two-way ANOVA on the effect of pretreatment, P < 0.001. Bonferroni post-test versus pretreatment with BSA 
***P < 0.001 for migration towards MCP1, ^^^P < 0.001 for migration towards Hp. (d) Same as (c) performed with primary 
monocytes. Data are expressed as means ± SEM of migrated cells for at least four experiments. Two-way ANOVA on the 
effect of pretreatment, P < 0.0001. Bonferroni post-test versus pretreatment with BSA ***P < 0.001 for migration towards 
MCP1, ^^^P < 0.001 for migration towards Hp.
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internalization observed in these cells. Indeed, when
assessed by flow cytometry primary monocytes displayed
on average approximately 50% of the CCR2 surface
expression found in U937 cells (data not shown).
We next wanted to rule out the possibility that the
observed CCR2 disappearance from cell surface was due
to Hp interference with CCR2 binding to its antibody. To
this end U937 cells were treated with 0.5 mg/ml Hp or
BSA, fixed, permeabilized and stained. When compared to
cells similarly treated with Hp but not permeabilized,
these samples showed a 50% increase in CCR2 expression
(data not shown). This is a further indication that Hp
induces CCR2 internalization.
Hp promotes CCR2 signaling
The MAPK signal transduction pathway is activated in
response to the interaction of CCR2 with ligand, and
whether this pathway is implicated in the cellular events
leading to chemotaxis is a subject of debate [23]. To search
for additional evidence that Hp is able to activate CCR2
we assessed the phosphorylation state of extracellular sig-
nal-regulated kinase (ERK)1/2 in U937 cells previously
starved overnight (1% serum) and subsequently incu-
bated with Hp, with MCP1, or simply stimulated with
10% serum. As shown in the immunoblot and bar graph
of Figure 7 there was a significant induction of ERK1/2
phosphorylation in the Hp-treated sample (as compared
to starved cells, herein used as control), the intensity of
the signal being comparable to that observed for the
MCP1-treated samples. When cells were treated with the
CCR2 antagonist RS102895 (5 μM) a dramatic decrease in
ERK1/2 phosphorylation was observed in the cells treated
with Hp and with MCP1, but not in those serum stimu-
lated. Conversely, ERK1/2 phosphorylation was abol-
ished in all types of treatment (Hp, MCP1, 10% serum)
when U0126, the selective inhibitor of the ERK upstream
kinase MAP-ERK kinase (MEK) [24] was employed.
To further explore the capability of Hp to activate the
ERK1/2 pathway, a chemotaxis assay employing Hp and
MCP1 as chemotactic agents was performed with U937
cells previously incubated with U0126. The results of this
experiment, summarized in the bar graph of Figure 8a,
indicate that blocking the ERK1/2 pathway results in a
dramatic reduction (by almost 100%) of the capability of
Effect of haptoglobin (Hp) on calcium release in U937 cells Figure 4
Effect of haptoglobin (Hp) on calcium release in U937 cells. Upper panel: fura-2 acetoxymethyl ester (fura-2 AM) 
preloaded U937 cells untreated or pretreated with 500 ng/ml monocyte chemoattractant protein 1 (MCP1) or 5 μM RS102895 
were stimulated with 0.5 mg/ml Hp. Untreated cells were stimulated with 250 ng/ml MCP1 as a positive control. Bottom panel: 
quantification of [Ca2+]i rise in U937 cells. The rate of [Ca2+]i rise (percentage fura-2 AM saturation/s) induced by Hp was set to 
100% and the rate after pretreatments was calculated. The result is representative of three independent experiments.
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Hp and MCP1 to induce cell migration. Totally overlap-
ping results are obtained when primary monocytes are
employed (Figure 8b).
These data further strengthen the hypothesis that Hp
interacts with CCR2, since activation of ERK1/2 resulting
from exposure to Hp is drastically reduced upon pretreat-
ment of cells with a specific CCR2 antagonist. Further,
they suggest that an intact ERK1/2 pathway is required for
monocyte migration towards Hp and MCP1 to take place.
Discussion
The results described herein demonstrate that Hp is a
novel chemotactic factor and that its capacity to recruit
monocytes is mediated (at least in part) by an interaction
with the chemokine receptor CCR2. Evidence for this
interaction is based on the capacity of Hp to induce CCR2
internalization, the capacity of Hp to bind (albeit with
low affinity) CCR2 in vitro, Hp induced intracellular cal-
cium flux and Hp activation of the ERK 1/2 pathway. The
two latter properties reveal two additional novel roles/
functions for Hp. These concepts will be extensively dis-
cussed in the following paragraphs.
The in vitro evidence reported herein demonstrate that the
inflammation/adiposity marker Hp possesses chemotac-
tic potential at doses well within its human physiological
concentrations or less [3,15]. Further, our findings high-
light differences in the two Hp isoforms 1-1 and 2-2, with
the latter being a more potent monocyte chemoattractant.
This result should be considered in the light of clinical
studies on diabetic patients that indicate an association
between the presence of the Hp 2-2 phenotype and a more
frequent onset of complications (retinopathy or neuropa-
thy) [25,26] and cardiovascular disease (CVD) [27,28].
These data are extensively reviewed by Nakhoul et al. [29]
that, among other hypotheses, points to the greater
expression of markers of activation in macrophages of
type 2-2 (as compared to type 1-1), this implying a higher
inflammatory status in these patients. Our in vitro findings
reinforce this concept by attributing a direct effect of the
Hp phenotype on macrophage recruitment. The higher
capacity of type 2-2 to recruit macrophages could indeed
contribute to enhancing the local inflammatory status,
which in turn accelerates the onset of diabetic comorbidi-
ties and CVD [30].
The capacity of Hp to recruit monocytes/macrophages
also has important implications concerning its role in
WAT, where, as we described, its expression and release
are importantly induced during obesity [2,3]. Macrophage
infiltration in the WAT of obese individuals has been
attracting growing attention in the recent years, and has
been related to the low chronic inflammatory state that
often characterizes obesity status. In particular, the onset
of insulin resistance is thought to be determined, at least
in part, by the release of inflammatory factors produced
by macrophages.
An increasing amount of evidence points to factors
actively released by WAT or released into the extracellular
spaces when adipocytes undergo cell death and 'explode'
[31]. Among these factors particular attention has been
dedicated to the chemokine MCP1, which is considered a
main player in macrophage recruitment into WAT [32].
Convincing evidence of this role is derived from the
increased infiltration of macrophages observed in lean
mice overexpressing MCP1 in WAT [33] and, conversely,
from the significantly lower content of these cells in obese
mice deficient for this factor [12] as compared with con-
trols. However, macrophage content in the WAT of the
knockout models was not normalized to the levels
observed in lean mice, thus implying the presence of other
factors in the modulation of this phenomenon: based on
the evidence presented herein, Hp is certainly a good can-
didate to be considered one such factor.
The MCP1 receptor CCR2 is a G protein-coupled receptor
that is predominantly expressed on monocytes and it is
thought to be the key receptor mediating their influx into
tissues in the context of immune-based inflammation
[34]. Recent studies performed in vivo in CCR2 knockout
(KO) obese animals demonstrated that this role can be
extended to the recruitment of monocytes into the adi-
[125I]Monocyte chemoattractant protein 1 (MCP1) displace- ment from chemokine (C-C motif) receptor 2 (CCR2) by  haptoglobin (Hp) Figure 5
[125I]Monocyte chemoattractant protein 1 (MCP1) 
displacement from chemokine (C-C motif) receptor 
2 (CCR2) by haptoglobin (Hp). U937 cells were incu-
bated with the indicated Hp concentrations for 1 h at room 
temperature and the specific radioactivity was measured by γ 
counter after free from bound separation. The graph shows 
one experiment representative of three.
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pose tissue of obese subjects [13]. Our work suggests that
this receptor may play this role not only by interacting
with its high affinity ligand MCP1, but also by interacting
with a lower affinity ligand represented by Hp, as recipro-
cal interference of the two molecules in their capacity to
attract monocytes and to induce calcium release indicates.
It has already been proved that chemokines that behave as
specific agonists for other chemokine receptors can bind
to CCR2 acting as agonists or antagonists [21,35]. Hp
could by itself induce migration of mononuclear phago-
cytes to sites of inflammation even in the absence of
MCP1. It is worth noting that one of the major features of
inflammatory chemokines is their inducible expression
[36], whereas upregulation of Hp is an established
chronic condition during obesity. In this context we can
see Hp as a 'modulator' of monocyte/macrophage chem-
oattraction via chemokine receptor 2.
An aspect that differentiates Hp from MCP1 concerns its
relative abundance both in plasma, where Hp is 108 to 109
times more concentrated than MCP1 (0.3 to 3 mg/ml ver-
sus 100 to 400 pg/ml) [15,37] and in the WAT of a lean
individual, where Hp is undoubtedly expressed [2,38]
whereas MCP1 is almost undetectable [12,33]. These dif-
ferences should be taken into account when comparing
the chemotactic potency of these molecules in vitro: if
doses in the ng range (10 to 500), such as those required
for MCP1, were sufficient for Hp to recruit macrophages,
this would result in a very aspecific and potentially harm-
ful effect, taking place in several areas of the body. Conse-
quently, it is conceivable that Hp chemotactic action is
associated with the high protein concentrations deter-
mined by accumulation of the protein in the WAT of
obese individuals.
Tissue distribution also differentiates MCP1 from Hp.
MCP1 abundance in WAT is prevalently due (more than
80%) to its expression in the SVF [39] and a recent study
by Chung et al., [40] indicates that MCP1, along with a
number of chemokines and cytokines, is also abundantly
expressed in preadipocytes, which play a major role in the
inflammatory state of the adipose tissue. Notwithstanding
the relevance of MCP1 in macrophage recruitment in
WAT, the findings reported above suggest that the MCP1
increase observed in obesity is derived from a number of
cell types, including macrophages. As findings by do Nas-
cimento et al. clearly indicate [5], Hp gene expression and
release are instead almost totally confined to the adi-
pocyte fraction of WAT. Further, our unpublished obser-
Haptoglobin (Hp) induces chemokine (C-C motif) receptor 2 (CCR2) internalization Figure 6
Haptoglobin (Hp) induces chemokine (C-C motif) receptor 2 (CCR2) internalization. U937 cells and primary 
monocytes were incubated for 60 min at 37°C, 5% CO2 with increasing concentrations of Hp or monocyte chemoattractant 
protein 1 (MCP1) as positive control. The relative surface expression of CCR2 was determined by flow cytometry after stain-
ing with monoclonal antibodies to the chemokine receptor. (a) Bar graph showing the relative mean fluorescence on U937 
cells. The dark-striped white bar shows CCR2 expression on U937 cells without treatment. The white bar indicates the per-
centage of receptor present on the surface after incubation with MCP1 (10 μg/ml) and the black bars indicate the percentage 
of receptor present on the surface after incubation with Hp at the indicated concentrations. (b) Bar graph showing the relative 
mean fluorescence on primary monocytes. The dark-striped white bar shows CCR2 expression on U937 cells without treat-
ment. The white bar indicates the percentage of receptor present on the surface after incubation with MCP1 (10 μg/ml) and 
the black bars indicate the percentage of receptor present on the surface after incubation with Hp at 8.7 μM. Data are 
expressed as means ± standard error of the mean (SEM) of three independent experiments. Student t test on the effect of 
treatment versus control: *P < 0.05; **P < 0.01; ***P < 0.001.
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vations and a proteomic analysis carried out on different
stages of adipose conversion revealed that Hp gene expres-
sion is linked to the acquisition of the mature adipocyte
phenotype [41]. Therefore Hp is one of those few inflam-
matory molecules specifically expressed by adipocytes
within WAT. In summary, these observations suggest that
Hp plays a role in monocyte/macrophage recruitment to
WAT in conditions slightly different than those typical of
MCP1. Those conditions could be part of the switch that,
according to Lumeng et al. takes place in the WAT during
obesity [42] when alternatively activated macrophages,
producing anti-inflammatory molecules, are replaced by
classically activated macrophages producing inflamma-
tory molecules.
We can therefore speculate that Hp participates mainly in
the first part of the process, when adipocytes undergoing
the initial effects of weight gain, start producing an
increased concentration of molecules, including Hp, that
activate the recruitment of other CCR2+ monocytes or
that, likely, induce changes in the expression profile of the
resident macrophages, which in turn recruit other mono-
cytes (for instance by overexpressing MCP1). Our hypoth-
esis of Hp as a modulator for monocyte/macrophage
attraction to WAT does not underestimate the major role
played by MCP1 or the other chemokines binding CCR2.
In fact, we cannot exclude the possibility that Hp-induced
functional responses observed in monocytes are not
exclusively due to Hp/CCR2 interaction, but are also due
to the action of the glycoprotein on other chemokine
receptors. In this regard it is interesting to observe the dif-
ferent potency shown by Hp in inducing calcium release
in lymphocytes stably expressing CCR2 and in mono-
cytes. If for the former the Hp-induced [Ca2+]i signal is less
than half of that induced by MCP1, in the case of mono-
cytes calcium mobilization is equally induced by the two
factors. This may suggest the existence of Hp-responsive
receptors, other than CCR2, expressed by monocytes and
not by pre-B lymphocytes.
This study also demonstrates for the first time that Hp is
able to induce calcium release and to activate ERK1/2
MAP kinase. This introduces remarkable additions to the
functions and properties classically attributed to Hp. As a
matter of fact this glycoprotein, so far considered a player
in actions mostly occurring in the extracellular environ-
ment (hemoglobin transportation, antioxidant capaci-
ties), seems to be capable of interfering with the cascade
of events activated by calcium signaling among which an
intracellular pathway playing a pivotal role in several
physiological and pathological conditions. Indeed,
cytosolic alterations of calcium ion concentrations are an
integral part of signal transduction [43] and reported evi-
dence indicates that in monocytes calcium is a determi-
nant second messenger in the induction of the
inflammatory response orchestrated by nuclear factor
(NF)κB [44]. This implies that the elevated Hp levels
observed in the WAT of obese subjects [2] may be relevant
in determining an increase in the production of inflam-
matory molecules (cytokines, chemokines) in resident or
in newly recruited monocytes.
The role of MAPK pathways in monocytes migration has
been previously investigated. As reported by Ashida and
collaborators [23] in the established THP1 cell line of
monocytes, ERK1/2 is responsible for integrin activation
Haptoglobin (Hp) induces extracellular signal-regulated  kinase (ERK) activation in monocytes Figure 7
Haptoglobin (Hp) induces extracellular signal-regu-
lated kinase (ERK) activation in monocytes. U937 cells 
were serum starved with 1% serum overnight. Cells were 
then pretreated or not treated with U0126 (10 min, 1 μM) 
or RS102895 (30 min, 5 μM) prior to incubation with 10% 
serum, monocyte chemoattractant protein 1 (MCP1) (200 
ng/ml) or Hp (0.5 mg/ml) for 2 min. Harvested cells were 
lysed and extracted proteins were separated on 12% SDS 
polyacrylamide gel (50 μg per lane). Activation of ERK1/2 
was detected with anti-phospho-ERK antibody. The mem-
brane was stripped and reprobed with anti-ERK1/2 antibody 
for internal control. In the bottom panel, the bar graph 
shows the quantification of pERK1/2. Data are expressed as 
means ± standard error of the mean (SEM) for three experi-
ments. Student t test on the effect of serum, MCP1 and Hp 
versus serum starved cells on ERK1/2 activation. ***P < 
0.001. Two-way analysis of variance (ANOVA) on the effect 
of pretreatment with U0126 or RS102895 on ERK1/2 activa-
tion induced by serum, MCP1 and Hp, P < 0.0001. Bonferroni 
post-test. ^^^P < 0.001 versus serum stimulated cells, §§P < 
0.01 versus MCP1 stimulated cells, °°P < 0.01 versus Hp 
stimulated cells.
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but not for chemotaxis, which is under the control of Rho
kinase and p38 MAPK. Conversely, according to our data
on U937 cells ERK1/2 is indeed implicated both in MCP1-
dependent and Hp-dependent chemotaxis.
Conclusions
This study demonstrates for the first time that Hp is able
to recruit monocytes (macrophages) by interacting with
the chemokine receptor CCR2. This discloses a novel
function for this molecule, which is upregulated in the
WAT of obese subjects and which could participate to the
massive infiltration of monocytes observed in obesity.
Further, we have shown that by pharmacologically inhib-
iting CCR2 we could block cell migration to Hp, further
strengthening the notion that drugs for the obesity-
induced inflammatory state could be developed by acting
on this receptor. In this regard pharmacological inhibi-
tion of the ERK1/2 CCR2 downstream pathway should
also be considered as a possible therapeutical intervention
to prevent macrophage infiltration into WAT.
Methods
Cell culture
Human U937 monocytic cells were purchased from
American Type Culture Collection (ATCC Manassas, VA,
USA). Cells were maintained as a monocytic cell suspen-
sion in T-75 flasks containing RPMI 1640 medium sup-
plemented with 10% fetal bovine serum and antibiotics at
37°C in 5% CO2, and cultures were split every 3 to 5 days.
The murine pre-B cell line 300.19 stably transfected with
human CCR2 receptor was a kind gift of M Uguccioni, IRB
Bellinzona, Bellinzona, Switzerland [21].
300.19 cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum (FCS), 1% non-essential amino
acids, 1 mM sodium pyruvate, 0.05 mM β-mercaptoetha-
nol, 50 U/ml penicillin, 50 mg/ml streptomycin, 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and 2 mM glutamine at 37°C in 5% CO2. Cells
were split every 2 to 3 days and positive clones were
selected in the presence of 1.5 μg/ml puromycin (Sigma,
St Louis, MO, USA).
Isolation of monocytes
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from Buffy coats from healthy donor male subjects
(aged 20 to 40 years old) obtained from the Blood Trans-
fusion Center of the Cisanello University Hospital (Pisa,
Italy). Blood was diluted 1:4 with a solution containing
phosphate-buffered saline (PBS) pH 7.2, 0.5% BSA and 2
mM ethylenediaminetetra-acetic acid (EDTA) and then 35
ml of this solution were carefully layered over 15 ml
Ficoll-Paque (density = 1.077 g/ml) in a 50 ml conical
tube and centrifuged at 400 g for 30 min. The interphase
cells (PBMCs) were transferred to a new 50 ml conical
tube filled with PBS/EDTA and centrifuged at 300 g for 10
min. Then, the pellet was washed for removal of platelets
by spinning at 200 g for 10 min. Monocytes were isolated
from PBMCs by magnetic bead separation using Human
monocyte isolation kit II (Miltenyi Biotec, Bergisch Glad-
bach, Germany) resuspended in complete RPMI with 10%
FBS and antibiotics, and cultured overnight prior to use.
Chemotaxis assays
Chemotaxis assays were performed in 48-well Boyden
microchambers (AP48, Neuro Probe, Cabin John, MD,
USA). In the bottom wells of the chamber we added 30 μl
of a serum free 0.1% BSA RPMI solution containing one
of the following peptides: human Hp (Sigma, catalog no.s
H3536, H0138 and H9762 respectively for the 95% pure
mixture, and for the 98% pure 1-1 and 2-2 phenotypes),
human MCP1 (Peprotech, Rocky Hill NJ, catalog no. 300-
04). BSA at a concentration of 1 mg/ml was used as a neg-
ative control. An uncoated 10-μm thick polyvinylpyrro-
lidone-free polycarbonate filter with a pore size of 5 μm
was placed over the samples (Neuro Probe, Gaithersburg,
MD). The silicon gasket and the upper piece of the cham-
ber were applied, and 50 μl of the cell suspension (1 × 105
to 2.5 × 105/50 μl) was placed into the upper wells. Cells
were in some cases (referred to as pretreatments) incu-
bated for 45 min at 37°C with MCP1, Hp or BSA or the
CCR2-specific antagonist RS102895 (see Results section
and Figure legends for concentrations). Following the
treatment cells were pelleted, washed and finally resus-
pended in a suitable volume to perform chemotaxis.
The chamber was incubated in a humidified 5% CO2
atmosphere for 1.5 to 3 h at 37°C, and non-migrated cells
were gently wiped away from the upper surface of the fil-
ter. The filter was immersed for 30 s in a methanol-based
fixative and stained with Diff-Quick (Medion Diagnostics
AG, CH-3186, Düdingen, Switzerland) and then
mounted on a glass slide. Cells that had completely
migrated through the filter were counted in 10 random
high-power fields (HPF; original magnification × 400)
under light microscopy.
Intracellular calcium measurements
U937 and 300.19 cells were loaded with 3 μM fura-2 AM
(Molecular Probes, Invitrogen, San Diego CA) in PBS con-
taining 0.5% BSA for 30 min at room temperature in the
dark. After being washed in indicator free medium, cells
were resuspended at a density of 1 × 106 cells/ml in PBS/
0.5% BSA containing 1 mM CaCl2. After a further incuba-
tion of 30 min to allow complete de-esterification of intra-
cellular fura-2 ester cells were ready to be analyzed.
Pretreatments with MCP1 (500 ng/ml) and RS102895 (5
μM) were performed for 30 min at room temperature dur-
ing the indicator de-esterification. The cell suspension
(800 μl/sample) was then transferred into glass cuvettes.BMC Biology 2009, 7:87 http://www.biomedcentral.com/1741-7007/7/87
Page 12 of 14
(page number not for citation purposes)
Cells were stimulated with the appropriate chemokine
(250 ng/ml nM MCP1 or 0.5 mg/ml Hp) and real-time
data were recovered using a fluorometer (LS55; Perk-
inElmer, Watham MA). Data were analyzed using FL-Win-
lab Software (PerkinElmer) and expressed as the relative
ratio of fluorescence emitted at 510 nm after sequential
stimulation at 340 and 380 nm (excitation wavelengths).
Radioligand binding studies (whole-cell binding)
Binding studies were performed according to Sarau et al.
[45]. Briefly U937 cells (5 × 105), resuspended in RPMI
with 0.1% BSA and 25 mM HEPES (pH 7.4) (reaction
buffer), were incubated with [125I]MCP1 (4 ng/ml) in the
absence or presence of unlabeled Hp (0.25 to 2 mg/ml) or
an excess amount of MCP1 (1 μg/ml) for 1 h at room tem-
perature in Eppendorf microcentrifuge tubes (final reac-
tion volume 100 μl). The binding reaction was terminated
by placing the incubation mixture over a 10% sucrose
cushion (375 μl) and centrifuging at 14,000 rpm for 2 to
3 min to separate bound from free ligand. The resultant
supernatant fraction was discarded, and the amount of the
radioactivity associated with the pellet was determined by
γ scintillation spectrometry. The percentage of [125I]MCP1
displacement from the receptor was calculated using T -
samplei/T - NS, where T is the total radioactivity measured
in the absence of Hp or MCP1, samplei is the radioactivity
measured when a given concentration of Hp was added
and NS (not specific) is the radioactivity measured in the
presence of an excess amount of MCP1.
CCR2 internalization
Incubations of U937 cells or primary monocytes with the
different ligands have been performed for 60 min at
37°C, 5% CO2 in RPMI medium supplemented with 1%
BSA. Internalization of CCR2 was followed by flow
cytometry using phycoerythrin-conjugated mouse mono-
clonal anti-human (25 mg/ml; R&D Systems, Minneapo-
lis MN) resuspended in FACS buffer (PBS/1% BSA).
Isotype-matched control IgG was used for control stain-
ing. Cell associated fluorescence was analyzed by flow
cytometry (FACScan, Becton Dickinson, Mountain View,
CA, USA).
CCR2 internalization was also evaluated in fixed and per-
meabilized cells. Briefly, before staining, cells were incu-
bated on ice in 1% paraformaldehyde for 2 min, washed
and then permeabilized with 0.15% saponin for 30 min
on ice.
ERK phosphorylation
U937 cells were aliquoted into a Petri dish at 5 × 106 cells/
sample in 1.0 ml of CCR2 binding buffer and prewarmed
to 37°C for 10 min. Compound was added for 5 min
before stimulation. The samples were stimulated with
mCCL2 (30 nM; R&D Systems) for 1 min. The cells were
quickly pelleted, the supernatant was removed, and 100
μl of ice-cold lysis buffer containing 50 mM Tris pH 7.4,
150 mM NaCl, 0.25% Na-deoxycolate, 1% nonyl phenox-
ylpolyethoxylethanol (NP40), protease inhibitor cocktail
(Roche, Mannheim Germany, catalog no. 11836153001),
phosphatase inhibitor cocktail (1 and 2, Sigma catalog
no.s P-2850 and P-5726) was added. After 10 min on ice,
the samples were microfuged at 13,000 rpm for 10 min at
4°C, and the supernatants were collected. For western
analysis, 15 μl of 2 × Laemmli sample buffer was added to
15 μl of cell extract, and the samples were boiled for 5 min
and loaded onto 12% Tris-glycine gels (Bio-Rad, Hercules
CA). Following electrophoresis and transfer onto
poly(vinylidene difluoride) membrane, the membranes
were probed with either a rabbit polyclonal anti-phos-
pho-ERK antibody or rabbit polyclonal anti-ERK to detect
total ERK protein (1/1,000 dilution; Cell Signaling Tech-
nology, Danvers MA) followed by a HRP-conjugated goat
Haptoglobin (Hp)-mediated chemotaxis is inhibited by block- ing extracellular signal-regulated kinase (ERK)1/2 intracellular  pathway Figure 8
Haptoglobin (Hp)-mediated chemotaxis is inhibited 
by blocking extracellular signal-regulated kinase 
(ERK)1/2 intracellular pathway. (a) Bar graph showing 
the effect of pretreatment with U0126 (10 min, 1 μM at 
37°C, black bars), or bovine serum albumin (BSA) (1 mg/ml, 
white bars) on the capacity of U937 cells to migrate towards 
monocyte chemoattractant protein 1 (MCP1) (100 ng/ml) 
and Hp (0.1 and 0.5 mg/ml). Data are expressed as means ± 
standard error of the mean (SEM) of migrated cells for at 
least three experiments. Two-way analysis of variance 
(ANOVA) P < 0.001. Bonferroni post-test versus pretreat-
ment with BSA ***P < 0.001. (b) As (a) using human primary 
monocytes. Two-way ANOVA P < 0.001. Bonferroni post-
test versus pretreatment with BSA ***P < 0.001.
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anti-rabbit IgG antibody (1/2,000; Cell Signaling Tech-
nology). After washing the blots in PBS + 0.1% Tween 20,
the blots were developed with the enhanced chemilumi-
nescence detection system (Bio-Rad). The same mem-
branes were stripped and reprobed with anti-ERK2 for
normalization. Signals were acquired by Molecular
Imager Chemidoc XRS System (Bio-Rad) and their inten-
sity was quantified by using Quantity One software (Bio-
Rad).
Statistics
All values are expressed as means ± standard error of the
mean (SEM) for at least three independent experiments.
Pairwise comparisons (for example, CCR2 expression: on
cells preincubated with BSA versus cells preincubated with
Hp) were assessed by two-tailed Student t test. When more
than two groups were analyzed, two-way or one-way anal-
ysis of variance (ANOVA) followed by Bonferroni post-
test for selected comparisons (for example, pretreatment
with BSA versus pretreatment with MCP1) was used.
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